Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Recruiting

Phase 3

Sponsor:

Boehringer Ingelheim

Code:

NCT06151574

Conditions

Lung Cancer, Non-squamous, Non-small Cell

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

zongertinib

pembrolizumab

cisplatin

carboplatin

pemetrexed

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information